Silas Inman | Authors

June 08, 2022

Rivoceranib showed promising responses in regard to objective response rate and disease control rate when used in patients with recurrent or metastatic adenoid cystic carcinoma.

June 07, 2022

According to Timothy J. Whelan, MD, FASCO, radiotherapy is an inconvenient treatment. It can last daily for up to 5 weeks and it is a costly therapy. Study results shows that is can safely be omitted in the treatment of some patients with luminal A breast cancers.

June 05, 2022

At the 2022 ASCO Annual meeting, trastuzumab dreuxtecan was found to be a superior standard of care therapy for patients with hER2-low, hormone-positive metastatic breast cancer.

June 05, 2022

Treatment with a Claudin18.2–specific chimeric antigen receptor T-cell therapy has demonstrated either a response or stable disease in patients with heavily pretreated advanced gastric and pancreatic adenocarcinoma.

June 04, 2022

A safety follow-up analysis of the randomized phase 3 DESTINY-Breast03 study reinforced the risk-benefit profile of trastuzumab deruxtecan compared with trastuzumab emtansine in patients with HER2-positive unresectable or metastatic breast cancer

June 04, 2022

According to Michael Dickinson, MBBS, glofitamab is a highly active drug. The agent showed durable response in patients with heavily pretreated large B-cell lymphoma.